Document Detail


3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication.
MedLine Citation:
PMID:  18171283     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Small molecular inhibitors of hepatitis C virus (HCV) replication provide remarkable potency, but the rapid selection of resistance mutations will require that these agents be used in combination for clinical treatment. Using a model HCV replicon system, we have extended prior in vitro studies of double combinations of candidate small molecular inhibitors to studies evaluating the simultaneous use of 3 agents. This was done in an effort to anticipate conditions that might ultimately be required clinically. We formally demonstrate synergistic antiviral activity with 3-drug combinations in this model, further supporting the concept of clinical investigations of combination therapy for HCV infection.
Authors:
Christian Grünberger; David L Wyles; Kelly A Kaihara; Robert T Schooley
Related Documents :
8135783 - Complete 5' noncoding region is necessary for the efficient internal initiation of hepa...
25184113 - Efficacy and tolerability of entecavir for hepatitis b virus infection after hematopoie...
20206833 - Hiv-1 gp41 fusion intermediate: a target for hiv therapeutics.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  197     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-03     Completed Date:  2008-03-04     Revised Date:  2014-09-05    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  42-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / pharmacology
DNA-Directed DNA Polymerase / antagonists & inhibitors*
Drug Synergism
Hepacivirus / drug effects*,  physiology
Humans
Microbial Sensitivity Tests
Protease Inhibitors / pharmacology*
Virus Replication / drug effects*
Grant Support
ID/Acronym/Agency:
AI-36214/AI/NIAID NIH HHS; AI069989/AI/NIAID NIH HHS; K08 AI069989/AI/NIAID NIH HHS; K08 AI069989-02/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Protease Inhibitors; EC 2.7.7.7/DNA-Directed DNA Polymerase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  C-reactive protein mediates the effect of apolipoprotein E on cytomegalovirus infection.
Next Document:  Functional suppression by FoxP3+CD4+CD25(high) regulatory T cells during acute hepatitis C virus inf...